To include your compound in the COVID-19 Resource Center, submit it here.

SomatoKine IGF-1/BP3: Phase II data

INSM updated previously reported open-label Phase II data showing that SomatoKine decreased daily insulin requirements and daily

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE